A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 in Healthy Participants and in Patients With Type 2 Diabetes
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 67
- 试验地点
- 2
- 主要终点
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
研究概览
简要总结
The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 in healthy participants and participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study has two parts (part A and B). Each part will last up to 10 weeks and may include up to either 13 (part A) or 19 (part B) visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males that agree to use an effective method of contraception or agree to remain abstinent
- •Females that are not of childbearing potential due to postmenopausal status or due to surgical sterility
- •Part A only:
- •Are overtly healthy
- •Body mass index (BMI) of 18.5 to 35 kilograms per meter squared (kg/m²)
- •Part B only:
- •Have been diagnosed with Type 2 Diabetes (T2D) for at least 6 months prior to screening
- •Be treated for T2D with stable dose of metformin, a stable dose of a dipeptidyl peptidase-4 (DPP-4) inhibitor with or without metformin, or a stable dose of a glucagon-like peptide-1 (GLP-1) receptor agonist with or without metformin for at least 3 months prior to screening
- •BMI of 27 to 40 kg/m²
排除标准
- •Have undergone any form of bariatric surgery
- •Have used or intend to use medications that promote weight loss within 3 months prior to screening, for the duration of the study
- •Part A only:
- •Have fasting plasma glucose (PG) levels ≥7 millimoles per liter (mmol/L) (≥126 milligrams per deciliter (mg/dL)) at screening
- •Have Hemoglobin A1c (HbA1c) level ≥ 6.5% (48 millimoles per mole (mmol/mol)) at screening
- •Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >20% and 10%, above the upper limit of normal (ULN), respectively. Elevation of total bilirubin level is considered acceptable in case of Gilbert's disease (with a normal direct bilirubin)
- •Part B only:
- •Have Type 1 Diabetes or latent autoimmune diabetes in adults
- •Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
- •Have known proliferative diabetic retinopathy, diabetic maculopathy, or severe nonproliferative diabetic retinopathy
- •Present comorbid conditions commonly associated with diabetes (for example, hypertension, hypercholesterolemia, hypothyroidism) unless they are well-controlled with stable medication
- •Have had an episode of severe hypoglycaemia within 6 months prior to screening, or have a history of hypoglycaemia unawareness or poor recognition of hypoglycaemia
- •Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase >2 × ULN at screening
- •Have a resting heart rate of <50 or >100 beats per minute
- •Have an estimated glomerular filtration rate (<60 milliliter/minute (mL/min)/1.73 m2, or a level of estimated glomerular filtration rate that would contraindicate the use of metformin per the label in the respective country
- •Have a screening calcitonin ≥20.0 picograms per milliliter (pg/mL)
- •Fasting serum triglyceride level of >500 mg/dL at screening
- •Have serum AST or ALT >3 × ULN or TBL >1.5 × ULN (except for participants diagnosed with Gilbert's syndrome)
- •Have taken any prescription medication that are specifically indicated for lowering serum triglycerides within the last 3 months
- •Have taken within the last 3 months any medications that interfere with absorption of dietary cholesterol or fats
- •Use of medications known to prolong the QT/QTc interval
- •Treated only with diet and exercise at study entry
研究组 & 干预措施
LY3457263 - Part B
Escalating single doses of LY3457263 administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
干预措施: Dulaglutide (Drug)
LY3457263 - Part A
Escalating single doses of LY3457263 administered subcutaneously (SC) to healthy participants
干预措施: LY3457263 (Drug)
Placebo - Part A
Placebo administered SC to healthy participants
干预措施: Placebo (Drug)
LY3457263 - Part B
Escalating single doses of LY3457263 administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
干预措施: LY3457263 (Drug)
Placebo - Part B
Placebo administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
干预措施: Dulaglutide (Drug)
Placebo - Part B
Placebo administered SC in combination with Dulaglutide administered SC to participants with type 2 diabetes
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
时间窗: Baseline through Day 42
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
次要结局
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3457263(Day 1 through Day 42)